Diferencia entre revisiones de «Oncologic therapy related adverse events»
Sin resumen de edición |
|||
| Línea 15: | Línea 15: | ||
==Differential Diagnosis== | ==Differential Diagnosis== | ||
{{oncologic therapy adverse events}} | {{oncologic therapy adverse events}} | ||
==Evaluation== | ==Evaluation== | ||
==CAR-T cells medications== | |||
===Tisagenlecleucel (Kymriah)=== | |||
===Axicabtagene ciloleucel (Yescarta)=== | |||
*Indications: Acute lymphoblastic leukemia and Large B-cell lymphoma | |||
==Management== | ==Management== | ||
Revisión del 20:47 4 mar 2020
Background
Clinical Features
- Many novel oncologic therapies and Biologic immunomodulators adverse reactions may mimic common ED presentations such as sepsis.
Types of novel oncologic agents
- Genetically engineered T cells
- CD19–chimeric antigen receptor (CAR)-T cell therapy
- Monoclonal Antibodies against PD-1 checkpoints
- Small-molecule inhibitors
- Antibody-drug conjugates
- Immunotoxins
- Bispecific T-cell engagers
Differential Diagnosis
- Decreased cellular immunity which an cause reactivation or new
- Neurologic syndromes
- Hematologic side effects
- Cardiac effects
- Allergic reactions
- Pulmonary
- Endocrine
- GI
- Perforations
- Clostridium difficile
- Acute bacterial infections
- Malignancies
- Non-melanoma skin cancers
- Lymphoma
Evaluation
CAR-T cells medications
Tisagenlecleucel (Kymriah)
Axicabtagene ciloleucel (Yescarta)
- Indications: Acute lymphoblastic leukemia and Large B-cell lymphoma